Beainy Ohanian
Family · Pasadena, CANPI 1629857255
Payments from drug & device makers
Across 82 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$317
- Revance Therapeutics, Inc.$263
- Galderma Laboratories, L.p.$198
- Amgen$185
- Axsome Therapeutics, Inc.$100
- Novo Nordisk$87
- plus $769 from 19 others
What the payments were for
- Food & beverage$1,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $317 |
| Revance Therapeutics, Inc. | 7 | $263 |
| Galderma Laboratories, L.p. | 7 | $198 |
| Amgen | 12 | $185 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Novo Nordisk | 4 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Bayer | 3 | $77 |
| Lilly USA, LLC | 3 | $77 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Exact Sciences | 2 | $55 |
| Verona Pharma, Inc. | 2 | $44 |
| AstraZeneca | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $43 |
| Almatica Pharma LLC | 2 | $34 |
| Merck | 1 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $32 |
| Vertex | 1 | $30 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| GSK | 1 | $28 |
| Pfizer | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Boston Scientific | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
How this compares
$1,919 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 13 | $9,465 |
| EliquisApixaban | 11 | $6,578 |
| Atorvastatin Calcium | 30 | $283 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $226 |
| Metformin Hcl | 31 | $215 |
| Gabapentin | 15 | $122 |
| Tamsulosin Hcl | 15 | $110 |
| Methylprednisolone | 11 | $107 |
| Alprazolam | 11 | $99 |
| Rosuvastatin Calcium | 16 | $96 |
| Ibuprofen | 14 | $88 |
| Simvastatin | 11 | $73 |
| Azithromycin | 18 | $70 |
| Cyclobenzaprine Hcl | 11 | $58 |
| Carvedilol | 13 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $317 | $9,46513 claims |
| PfizerEliquis | $27 | $6,57811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.
Other family in Pasadena
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.